Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Early Onset Pulmonary Events in Patients with Non-Small Lung Cancer or Other Cancers Taking Brigatinib or Other TKIs

Multiple Cancer Types

This phase II trial studies early onset pulmonary events in patients with non-small lung cancer and other cancers taking brigatinib or other TKIs. Severe side effects, including trouble breathing, coughing, pneumonia, and inflammation of the lungs (pneumonitis), have been seen in patients taking brigatinib. This study is being done to watch patients taking brigatinib and compare that experience with patients taking other drugs that also target ALK or ROS1 to study how often events like these occur. This study is also being done to observe patients who stopped brigatinib temporarily because of a suspected early onset pulmonary event, but then restarted brigatinib at the same dose to assess what experience they have.
Lung, Non Small Cell
II
Iams, Wade
NCT03389399
VICCTHO1885

Clinical Outcomes of Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer: An ATOMIC Consortium Analysis

Multiple Cancer Types

Lung, Non Small Cell
N/A
Iams, Wade
VICCTHO19141

A Phase 1 / 2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)

Multiple Cancer Types

Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and / or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Miscellaneous, Phase I
I/II
Iams, Wade
NCT03600883
VICCPHI18161

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Lung

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:- - Arm A: Tiragolumab plus atezolizumab and CE - Arm B: Placebo plus atezolizumab and CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).
Lung
III
Iams, Wade
NCT04256421
VICCTHO19137

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Multiple Cancer Types

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Lung, Non Small Cell
II
Iams, Wade
NCT03539536
VICCTHO18125

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Multiple Cancer Types

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Lung, Small Cell
III
Iams, Wade
NCT03703297
VICCTHO1901

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: